Answer
Obinutuzumab has a median elimination half-life of 26.4 days in patients with chronic lymphocytic leukaemia.
Sources for this answer
- Gazyvaro 1,000 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 22Document updated
Sources checked